Molecular Partners AG

Molecular Partners AG is a Swiss clinical‑stage biotech developing DARPin therapeutics for oncology and ocular diseases. Phase III lead Abicipar treats wet AMD, while MP0250 addresses multiple myeloma, bolstering a growing pipeline.

Headquarters: Switzerland (CHE)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 158
HQ: Schlieren

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
MOLN	Molecular Partners AG Cap: 0.1B	EQUITY	EBS	CHF	CH0256379097	Active	📈